8-K: PMGC Holdings Terminates License Agreement with INmune Bio

PMGC Holdings Inc. and INmune Bio, Inc. have mutually agreed to terminate their License Agreement, effective February 27, 2025.

Summary

• PMGC Holdings Inc. (formerly Elevai Labs Inc.) and INmune Bio, Inc. have terminated their License Agreement effective February 27, 2025.
• The original License Agreement, entered into on January 22, 2024, granted PMGC Holdings certain rights to INmune Bio's EMx technology for cosmetic products.
• An amendment to the License Agreement was made on July 12, 2024, modifying payment terms.
• With the termination, no further fees will be due to INmune Bio.
• PMGC Holdings is considering other in-licensing opportunities with INmune Bio but has not made any decisions.

Sentiment

Score: 5

Explanation: The document describes a neutral event (termination of an agreement). The sentiment is neither particularly positive nor negative, as it simply reflects a business decision.

Positives

• The termination simplifies PMGC Holdings' obligations, as no further fees are due to INmune Bio.
• PMGC Holdings is evaluating potential in-licensing opportunities for other biotechnology assets from INmune Bio, which could lead to new opportunities.

Negatives

• PMGC Holdings has lost the rights to INmune Bio's EMx technology for cosmetic products.
• The company will need to find alternative technologies or strategies for its medical aesthetics skincare market products.

Risks

• The termination of the License Agreement could impact PMGC Holdings' product development and commercialization plans in the medical aesthetics skincare market.
• There is no guarantee that PMGC Holdings will successfully in-license other biotechnology assets from INmune Bio.

Future Outlook

PMGC Holdings is evaluating potential in-licensing opportunities for other biotechnology assets from INmune Bio but has not made any decisions at this time and may revisit the opportunity in the future.

Management Comments

• RJ Tesi, CEO of INmuneBio, and Graydon Bensler, CEO of PMGC Holdings, both signed the Mutual Termination of License Agreement.

Industry Context

License agreements are common in the biotechnology and pharmaceutical industries, allowing companies to leverage each other's technologies and expertise. Termination of such agreements can signal a change in strategic direction or a reassessment of the value of the licensed technology.

Comparison to Industry Standards

• It is difficult to compare this specific termination to industry standards without knowing the specific financial terms and strategic rationale behind the original agreement.
• License agreements in the biotech industry often involve upfront payments, milestone payments, and royalties on future sales.
• Terminations can occur for various reasons, including failure to meet milestones, changes in market conditions, or strategic shifts by either party.

Stakeholder Impact

• Shareholders may be concerned about the impact of the termination on PMGC Holdings' future prospects.
• Employees involved in the development and commercialization of products based on the licensed technology may be affected.
• Customers may experience changes in the availability or features of PMGC Holdings' skincare products.

Next Steps

• PMGC Holdings will need to determine its next steps in the medical aesthetics skincare market.
• PMGC Holdings may pursue in-licensing opportunities with INmune Bio or explore alternative technologies.

Key Dates